Home | miyaokalab

Genome Editing in Human iPS Cells to Study and Cure Disease

Human iPS (induced pluripotent stem) cells have the potential to allow us to study diseases in virtually any type of human cell, and develop cell transplantation-based therapies. Our team is developing and improving genome editing technology in iPS cells. We are developing novel isogenic iPS cell-based disease models, and correcting mutations in iPS cells from patients, a critical step in transplantation-based therapies. Our current focus is on diseases affecting cardiomyocytes and hepatocytes. →More

English

日本語

News

2025. 12. 3.　Daisuke Matsumoto"s paper on development of a screening system for Cas9 variants with higher HDR activities is published in Journal of Biomedical Science!

2025. 12. 1.　Yuka Satake joins the lab a s an Intern!

2025. 10. 1.　Shana Shiikawa joins the lab a s an Intern!

2025. 6. 24.　More matured phenotypes including stronger and faster contraction by cardiomyocytes derived from tetraploid iPS cells generated by cell fusion are out in bioRxiv.

2025. 6. 7.　Isolation and analysis of >1,000 genome-edited iPS cell clones in collaboration with Yamaha Mortor is published in Stem Cell Research & Therapy!!

2025. 4. 3.　Gou Takahashi and Yuichiro Miyaoka contribute to the book, CRISPR-Cas Methods : Volume 3

2025. 4. 1.　Ittetsu Nakajima is awarded the ISSCR Travel Award!

2025. 4. 1.　Moe Sato and Haruka Nakayama join the lab as a graduate student and an intern, respectively!

2025. 3. 2.　Lab ski & snowboard trip to Madarao

2025. 3. 1.　Daisuke Matsumoto comments in Springer Nature Japan Research Advisory Forum 2024 (in Japanese).